It is suggested that therapeutic strategies aiming to reduce ROS levels and RIPK1 activity, as well as to recover TDP-43 homeostasis, could be useful for ALS patients carrying a dysfunctional TBK1 protein. The gene discussed is TBK1; the disease is amyotrophic lateral sclerosis.